explore -WSS

explore

author：knowledge 2025-10-02 22:56:48 - browse：6171

An effective treatment for Alzheimer’s disease has long been a holy grail in the pharmaceutical industry. In early June, some hope appeared when the FDA agreed that the anti-amyloid antibody lecanemab (to be sold by Eisai as Leqembi) outperformed placebo in trials. It is expected to receive full approval by July 6.

But this may not necessarily be purely good news.

On the latest episode of the “First Opinion Podcast,” physician and professor Jason Karlawish argues that lecanemab and other promising new drugs, such as donanemab, will introduce complicated issues into the field of Alzheimer’s care. These medications require a great deal of testing and patient monitoring, trained physicians, and other resources in a system that is already stretched thin.

“Dr. Karlawish’s dream of reason would be … a training module for physicians to learn the key things they need to learn and then self-assess their comfort with the drug,” Karlawish said. “But that’s Karlawish’s dream of reason in a world that seems increasingly less reasonable sometimes.”

Karlawish is a professor of medicine, medical ethics and health policy, and neurology at the University of Pennsylvania’s Perelman School of Medicine. The conversation is based off his recent First Opinion, “The FDA needs a risk evaluation and mitigation strategy for Alzheimer’s drug lecanemab.“

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Gritstone Bio's cancer vaccine test, and more on Novartis' deal

WSS

Sanofi to acquire U.S. biotech Inhibrx in $2.2 billion deal

AI gets buy

Why Novartis is going to walk from its acquisition of MorphoSys

Bernie brings in new pharma CEOs to talk drug prices

Maisha Meds is a PBM, but don't call it that

Why CTE doesn’t keep Americans from enjoying the Super Bowl

hotspot

explore

leisure time

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What’s missing from the debate over nursing home staff minimums

Tori Bowie and the unacceptable rates of Black maternal death

A protest over insulin prices is seen as a fight for life

Virginia high school admissions case could be legal follow

The Biogen Aduhelm mess could happen again

The cancer drug shortage isn’t new — and neither are the solutions

HPV vaccine, cervical cancer study delivers historic results

Psychedelics group wrestles with new pharma identity

A single Democrat is willing to weaken Medicare negotiation power

Wikipedia

Bernie brings in new pharma CEOs to talk drug prices

Readout LOUD: Venture capital, Gilead, and more M&A

To bolster infectious disease surveillance, genomics powerhouses team up

Problems with a popular proposal to regulate AI in health care

Dana Farber says 6 studies to be retracted and 31 corrected

Readout Newsletter: Amgen, Regeneron, BGI Group and more

focus

hotspot

hotspot

Wikipedia